IRAK4: potential therapeutic target for airway disease exacerbations

Joseph A Jude; Reynold A Panettieri Jr

doi:10.1016/j.tips.2025.01.001

IRAK4: potential therapeutic target for airway disease exacerbations

Trends Pharmacol Sci. 2025 Jan 16:S0165-6147(25)00001-X. doi: 10.1016/j.tips.2025.01.001. Online ahead of print.

Authors

Joseph A Jude¹, Reynold A Panettieri Jr²

Affiliations

¹ Rutgers Institute for Translational Medicine and Science, Child Health Institute of New Jersey, Rutgers, The State University of New Jersey, 89 French Street, Suite 4210, New Brunswick, NJ 08901, USA.
² Rutgers Institute for Translational Medicine and Science, Child Health Institute of New Jersey, Rutgers, The State University of New Jersey, 89 French Street, Suite 4210, New Brunswick, NJ 08901, USA. Electronic address: [email protected].

PMID: 39824674
DOI: 10.1016/j.tips.2025.01.001

Abstract

Inflammatory lung diseases represent a significant healthcare burden. There is an unmet need for identifying therapeutic targets for inflammatory lung diseases, such as asthma, and chronic obstructive pulmonary disease (COPD). In a recent study, Sayers et al. validate the inhibition of interleukin (IL)-1 receptor-associated kinase (IRAK)-4 as a potential therapeutic strategy toward lung inflammation and inflammatory airway diseases more generally.

Keywords: COPD; Toll-like receptor, asthma; interleukin-1 receptor-associated kinase 4; lung inflammation.